Crucial Fact

  • Her favourite word was fact.

Last in Parliament November 2005, as Liberal MP for Edmonton Centre (Alberta)

Lost her last election, in 2006, with 39% of the vote.

Statements in the House

Supply May 13th, 2003

Mr. Chair, the hon. member raises a very important question. That is why, starting in 2004, we will have a Canadian health transfer, CHT, which will make absolutely plain to Canadians and to each of the provinces and territories how much money the federal taxpayer is sending to the provinces. That Canadian health transfer will include both the cash and the value of the tax points so it will be absolutely clear to Canadians, as it relates to those two components which have made up heretofore the Canadian health and social transfer, the amount of money either in cash or tax points being transferred to the provinces.

For fiscal 2003-04 that amount of money, including and reflecting the increase through the health reform fund and the cash increase, will be $38.8 billion. That includes the tax transfer, the cash and the new money for this coming fiscal year, which flowed out of the health reform agreement.

However the hon. member raises a really good point. Canadians want to know how many of their federal tax dollars, be it cash or tax points, are going to support health care. We are going to create a health transfer. It will be completely transparent and Canadians will know and be able to say to the provinces that this is how much cash they have and this is the value of theirs tax points. They then will be able to ask the provinces how much is their total health care expenditures, how much of it is federal and how much of it is provincial tax dollars and what are Canadians getting for that?

The federal government is putting in more money every year. “Am I getting better health outcomes” is the kind of question to which expanded reporting will provide an answer. Canadians have a right to those answers. Canadians want those answers. Things like the Health Council will help provide those answers and analyze where the money goes and whether we getting better health outcomes for the dollars that are spent.

Supply May 13th, 2003

The hon. member is probably aware that we participated in a fact finding exercise which recently resulted in the report on mental illnesses in Canada. This is the first statistical overview of mental illness in Canada and I would be the first to agree with the hon. member that this is a very serious question. Some people call it the orphan of the health care system. We are not different. It is true in other countries as well. That is no justification. We all realize that we need to ensure that mental health is integrated as a key component of our health care system.

I take heart from the fact that for example in my own province of Alberta, mental health is now integrated into the health regions so they can develop an integrated approach to both physical and mental health. Obviously that will be something interesting for us all to look at.

Let me also point out that the Canadian Institutes of Health Research dedicated over $30 million in the past fiscal year to fund research projects in universities, research institutes and teaching hospitals across our country that ultimately aim to improve the mental health of Canadians.

Supply May 13th, 2003

Mr. Chair, as I indicated in my comments, at the request of the minister of health from Ontario, who we all know has been working very hard on the front lines of SARS for these past number of weeks, the health council postponed a scheduled provincial-territorial-federal health minister's conference call to deal with the council.

I spoke with my co-chair, who is from the province of Nova Scotia, and she and I agreed that under the circumstances we wanted to ensure all our colleagues had the opportunity to participate. I would hope that no one would disagree that we should be willing to provide colleagues the opportunity to be prepared to participate in that discussion. That is why the meeting was cancelled from its scheduled time. However, I have made it plain, as has Minister Purves, that we hope to reschedule that conference call and in fact I would like to be able to do that some time next week.

Regarding the composition of the health council, the hon. member is right that we must ensure, as the first ministers' accord indicated, that stakeholders and public experts are represented in relation to the composition of the health council. This cannot be a council that is overburdened with government representatives. It is a council on which we have a wide variety of members representing different perspectives, backgrounds and abilities as it relates to health care in this country. One of the key aspects of whether this body will be credible or not is in terms of who is on this body and we cannot overburden it with so-called government representatives.

I did not read the comments this morning of Dr. Dana Hanson as condemnatory of public health in this country. Dr. Hanson and the CMA have expressed views before as they relate to public health infrastructure, and I take very seriously their constructive input into the public health infrastructure of this country. That is an infrastructure that needs to be national. It is an infrastructure that needs to be built by provinces, territories, local public health authorities, and the federal government. That is why we are working toward and have improved the integration of our public health infrastructure.

For example, since September 11 we have put in $102 million directly into public health programs in order to enhance our capacity to deal with a range of public health measures, not just bioterrorism but other kinds of challenges such as SARS. This funding supports more advanced equipment in our labs, which we saw at work during the SARS outbreak, training for emergency health providers, stockpiles of drugs, vaccines, and emergency supply locations across Canada, and real-time information sharing on disease incidents.

This speaks to what the Auditor General and others have spoken about in terms of enhanced surveillance and how we do that surveillance. It follows that when we get the information from local public health authorities, that information must be shared so that everybody in the public health chain has that information and can work with it, and use it in ways that they see fit.

I also want to point out that coming out of our experience with SARS, I have asked Dr. David Naylor, who is the dean of the faculty of medicine at the University of Toronto, to head up what I describe broadly as a lessons learned exercise. Part of Dr. Naylor's recommendations and his committee's recommendations will be to deal with the public health infrastructure: what works, where the gaps are, and what we need to move forward. I have put in my own two cents worth, which is not unusual for me some would say, in relation to the fact that maybe we need a CDC-like national entity in this country that would become the focal point or the go-to place for a host of health issues, including infectious disease control.

Next is marijuana. I want to clarify this issue because there is a lot of misunderstanding. The hon. member has taken the opportunity to ask me on many occasions whether I and my department are discharging our obligation around drug approvals and medical devices, whether we are making sure we have rigorous clinical trials in place, and whether we are analyzing the results of those clinical trials to determine medicinal benefits and adverse effects.

I would expect the hon. member would demand exactly the same of me in relation to any claim around medicinal marijuana. The clinical trials have not been done to date. I have asked my department to search globally. The clinical trials that we are doing now in Toronto and in Montreal under the auspices of the CIHR, our open clinical trials, will probably be the most comprehensive clinical trials ever done in the world in relation to whether there are medicinal benefits from marijuana. We are the Department of Health. The hon. member would be outraged if we let somebody use some product for an alleged medicinal purpose without the clinical trials.

I will not be criticized for doing clinical trials to determine the medicinal benefits. In the clinical trials, both closed, in Toronto and Montreal, being run at McGill in the case of Montreal, marijuana is provided to those who are participating in the closed trials. The open trials can involve anyone who has an exemption under our regulatory regime. If they wish to participate in the open trials, marijuana will be provided to them so they do not need to worry about source of supply. Anyone who has an exemption, applied for and granted, can receive to participate in that open trial marijuana provided by us and marijuana, might I add, that has been tested and standardized so we know exactly the product with which we are dealing. We will be able to draw medically sound and scientifically based conclusions from those open trials.

I do apologize to the hon. member. I got my mandatory and my voluntary mixed up in the answer. Let me clarify for the hon. member and anyone else. We are working with the Standards Board in relation to voluntary labelling, and the hon. member says it is a failure. I and my colleague, the Minister of Agriculture, are not ready to throw in the towel. We have asked, and my colleague, the Minister of Agriculture, has even provided additional resources for the work to continue to see if we can reach some agreement around voluntary labelling. However I understand that this is an important issue and I just want to reassure the hon. member that Health Canada, along with the CFIA, has a rigorous process in place for evaluating the safety of foods derived from biotechnology. We are not waiting for labelling to do that. That is part of our obligation.

Our regulations require that these products be reviewed by Health Canada prior to being sold in our country to ensure that there are no safety concerns. We will continue to examine our review processes for biotechnology derived products.

Supply May 13th, 2003

No, because then tobacco companies respond to those approaches. What I want to do is narrow the field, so that when we move we move in an effective way that deals with the real problem.

Supply May 13th, 2003

Mr. Chair, the hon. member is right in that my predecessor did indicate that he was going to take a look at the whole question of the “light” and “mild” descriptors on tobacco product packaging. After that, consultations were put in place and research has been done in relation to a number of important areas.

I am going to be quite candid with the hon. member, as he would expect. We want to make sure that when we move in this area, we have the science to back up the decisions we take. Otherwise we know full well that we will be spending a lot of time in court and a lot of taxpayers' dollars. What I would like to do is make sure that we have the science in place and we have done the research so that we have a compelling argument in relation to the descriptors “light” and “mild” and therefore, we can withstand any challenge, including a charter challenge, in relation to these descriptors.

Let me tell the hon. member that I take this issue very seriously. My department takes it very seriously. I would be wrong if I said that the scientific inquiry is over. In fact, we do not have all the answers as a matter of science at this point. I am also looking at the experience of the European Union. It has taken a somewhat different approach in terms of how it has dealt with these descriptors. I am looking at the experience of Brazil. I am looking at the approaches of various countries and then what tobacco companies do--

Supply May 13th, 2003

I am responding in terms of what we as a government did. I understand the hon. member wants us to be more sensitive. In essence he is suggesting that our compensation plan has been inadequate. What I am saying is that in fact the government has committed over $1.4 billion by way of compensation and assistance.

Not only have we paid the $875 million to fulfill our financial obligations to claimants under the 1986 to 1990 settlement agreement, we also have put aside some $525 million to provide care and improve blood regulation and surveillance. The $525 million is largely to provide care for those individuals who were infected with hepatitis C before 1986 and after 1990. An important component of that funding is the undertaking agreement which provides a transfer of $300 million to the provinces and territories for health care services to help ensure that individuals infected with hepatitis C do not incur out of pocket expenses.

Our plan is sensible. It is compassionate. It provides care to people living with hepatitis C.

Supply May 13th, 2003

Mr. Chair, again the hon. member has raised a very serious question, one on which I do believe the government has shown some considerable humanity and compassion to choose his language.

We have committed approximately $1.4 billion for compensating and assisting people infected with hepatitis C through the blood system. We as a federal government have paid $875 million to fulfill our financial obligations to claimants under the 1986 to 1990 hepatitis C settlement agreement. In fact, this all flows directly from Krever.

Supply May 13th, 2003

Mr. Chair, there are three things.

The hon. member raised the question around Quebec's allocation from various funds. Again, I can send him the details, but let me make it clear for example that the health reform fund of $16 billion over five years is a per capita fund, so it is easy to work out Quebec's allotment. The medical equipment fund is a per capita fund, therefore it is easy to work out Quebec's share of that fund. Some of the other funds or spending items that the hon. member identified are third parties. Canada Health Infoway receives an additional $600 million. That goes to Canada Health Infoway, which is an entity separate and apart from the government, but one where dollars will be spent in the provinces, including Quebec, to build on the good work around things like electronic patient records and telehealth. That is ongoing.

I want the hon. member to be aware that some of the funds are per capita, which are easy to work out. Other items he has mentioned are third party entities. The dollars go there and certainly funding of specific projects will take place in the province of Quebec as in other provinces.

The hon. member referred to the cigarette packages. The member was very wise to bring this to my attention and I thank him very much for doing that.

Just the other day I had the opportunity to see some of the packages and the hon. member is absolutely right. They do not meet the labelling requirements.

After he brought it to my attention some time ago, I asked my department to begin an investigation because there are a host of issues involved with those packages of cigarettes, only one of which is around labelling. Labelling does of course speak to the fact that there are no health warnings on those packages as it relates to the dangers of cigarette smoking. Also, as far as I can tell, there is no indication of the substances; there is no information around what is contained. I think we probably have a safety issue in relation to the tobacco leaf, where it came from, how it was grown, whether it was sprayed with various things.

There are a host of issues that we need to look at in relation to those packages. I have asked my department to follow up on that. I thank the hon. member very much for bringing that to our attention.

The hon. member asked me about the creation of the agency in relation to our assisted human reproduction legislation and the important challenge that many couples, a growing number of couples, face around infertility and their desire to start a family. There will be an agency created as proposed in the legislation. In fact this is the first time there will be any regulatory framework in this area. It is an area that needs some regulatory framework. The agency will be created as proposed in the legislation.

In Quebec, I have not had the opportunity to speak to the new minister of health, Mr. Couillard, in relation to his views around this agency, but I will be meeting with Mr. Couillard tomorrow in Montreal. I will certainly be more than interested in knowing the views of the new minister of health in relation to the creation of this agency.

Supply May 13th, 2003

Mr. Chair, I take the hon. member's admonition seriously. His first question was not short. Let me deal with the second question first and then I will come back to his lengthier question because that will take me some time if he wants me to go through all the funds.

In relation to HIV-AIDS, the hon. member is absolutely right that our strategy at the moment is an annual amount of $42.2 million. In fact that amount has not been increased over these past number of years. I have gone on record whenever I have met with national or local HIV-AIDS groups, for example from my own province of Alberta and my own city of Edmonton, that there is no question after the evaluation is done, which is ongoing at this very moment, I will be arguing very strenuously with my cabinet colleagues that we must increase the amount of money that goes into our annual national HIV-AIDS strategy.

I simply think that we know more today; science has helped us understand more about pharmaceutical interventions that help people live better lives and help them live longer while suffering with HIV-AIDS. We know there are gaps in our strategy. We know that more research needs to be done. We know that we need to put more emphasis on community support networks and support for families when a family member is suffering from HIV-AIDS.

I do not have to be convinced that more money is needed on an annual basis for the strategy. That is clear. It is a case of making sure that we do the evaluation which is required by Treasury Board, but more important, which is required because the community groups themselves are involved in that evaluation in identifying the gaps and the omissions. We must build on the good work that has been done especially by community based organizations and move forward.

The health committee is looking at this issue. I look forward to any recommendations that its members have for me in relation to how they think the strategy should be enhanced and built upon for the next phase.

The hon. member in his question worked through a number of funds that were identified in the first ministers accord in February. I do not know whether he wants me to go through them all, but I will identify a few and the hon. member can tell me to stop anytime he wants and I can send the information directly to his office.

He mentioned health services and official language minority communities. There is $89 million over five years to implement a training and retention initiative for health professionals and a community networking initiative to improve health services to minority official language communities.

At this point I will take the opportunity to congratulate and thank the chairs of the two committees. Hubert Gauthier from St. Boniface General Hospital in Winnipeg chaired the francophone minority committee on behalf of Health Canada. Eric Maldoff chaired the English speaking minority committee in relation to the provision of health services. Their work and the work of colleagues within the government led to a budget provision that the member has rightly identified to assist both official language minority communities in relation to the areas I have outlined.

The member mentioned pharmaceuticals management. Budget 2003 provides $190 million over the next five years to improve the timeliness of Health Canada's regulatory processes with respect to human drugs as an element of the overall health reform package. Access to safe, effective, new human drugs requires timely, efficient and scientifically rigorous review in all phases of the product cycle, including reviews and approvals by Health Canada.

This is an area to which I personally am very committed. We need to assess our existing drug approval process. We need to figure out how we move forward to ensure we have a globally benchmarked drug approval process that is second to none in the world, not only in terms of timeliness but obviously in terms of effectiveness, safety and cost effectiveness. That $190 million will help us discharge those kinds of obligations.

The hon. member mentioned nine funds. I have details in relation to all nine, but I get the sense that the hon. member does not want me to go through all nine. I would be happy to send the information in writing to the hon. member's office for his consideration.

Supply May 13th, 2003

Mr. Chair, may we wish the hon. member for Hochelaga--Maisonneuve a happy birthday.

First, Mr. Chair and hon. colleagues, I do want to introduce my officials who are here this evening because this will be a long night for all of us. Let me introduce Ian Green, my deputy minister; Ian Shugart, assistant deputy minister of health policy and communications; and Patrick Borbey, assistant deputy minister of corporate services at Health Canada. I thank all three of them, as I know my colleagues do, for being here this evening.

This is an opportunity to focus on issues of profound importance to every one of us: our health and our health care system and the role Health Canada plays in protecting and sustaining both those things.

We know that Canadians are strongly committed to their health care system and they have told us that they care deeply about the basic values at the heart of this system: equity and fairness. Therefore, any actions we take must be measured against these values. This is what Canadians want and this is what the Government of Canada, working together with the provinces and territories, must achieve.

I will start with a description of the context within which the government addresses health issues in general, and will then move on to the key components of our strategic priorities for this fiscal year.

The point of departure is the mandate of Health Canada, which consists in helping the people of Canada to maintain and improve their health.

As we all know, this is not a role that we can fulfill alone. All levels of government have important and complementary responsibilities in health, as do communities, the people working in our health system, primarily those on the front line, and individual Canadians.

Before I go on, I would like to take a moment to thank the many doctors, nurses and other health care professionals who have worked tirelessly without hesitation and in some cases at great personal sacrifice during these past two months. Their heroic efforts have helped ensure that SARS has been brought under control in Canada. Since this week is nurses week, I would like to say a special thanks to Canada's more than 100,000 nurses for the significant contributions they make every day to our quality of life.

Let me also highlight the excellent work of Health Canada's scientists, microbiologists, epidemiologists and others working in Ottawa and across the country. The crucial work of scientists at Health Canada's National Microbiology Lab in Winnipeg toward identifying the SARS associated coronavirus and in isolating genetic material from the virus was essential to the subsequent sequencing of the genome by the Genome Sciences Centre. I cannot overstate the importance of the contributions of Health Canada scientists working with their outstanding colleagues across the country.

The Government of Canada has clearly defined responsibilities in health which are anchored in collaborative work with others. Health Canada carries out these responsibilities through five broad roles. Let me take a moment to review these roles before speaking more specifically about some of Health Canada's priorities.

In relation to time, and I realize that there are undoubtedly questions my colleagues want to ask, I will not go into a lot of detail in terms of our roles. First, clearly we are a leader and a partner and this is demonstrated in part through Health Canada's responsibility to administer the Canada Health Act.

Second, we also have the role as funder. As we know, the federal government is a major contributor to health care through the Canada Health and Social Transfer. In 2003-04 transfers for health and social programs will total almost $38 billion.

Third, we have a combined role of guardian and regulator. Health Canada has been mandated by Parliament to protect Canadians against risks to health presented by health products, food and consumer goods. Furthermore, the department is now taking into account the broader smart regulation strategy that seeks to enhance Canada's place as a home for innovation while maintaining our standards for safety and stewardship.

Fourth, we have a service provider role. Health Canada is responsible for delivering health promotion, disease prevention and health care services to Canada's first nations and Inuit, making the Government of Canada the fifth largest health care budget in the country.

Fifth, we have a role as information provider. Canadians expect their federal government to provide reliable health information that they can use to maintain and improve their health.

As hon. members here this evening will have noticed from Health Canada's report on plans and priorities, we have identified five corporate priorities for the next three fiscal years. These priorities respond to current and emerging health issues as well as to government wide commitments. They are: health care system renewal; first nations and Inuit health; safety and health protection; balancing the health agenda; and improving accountability to Canadians. Let me briefly turn to each and discuss some of their major elements.

We spoke already this evening about health care system renewal. Our medicare system reflects some of the basic values of Canadians: the belief that all Canadians are entitled to quality health care based on need and not ability to pay; the conviction that no one should risk losing his or her life savings because that person becomes ill; and a determination to share the cost of health care through a publicly administered system.

These values are fundamental to the Government of Canada, as well as to the governments of the provinces and territories. Governments agree that our medicare system needs to change to reflect new challenges and new opportunities. That need was at the heart of the first ministers' health accord of last February. We have already talked about aspects of that, so I will reiterate that as a result of the accord Canadians will see fundamental structural changes to Canada's health care system over the next five years. Canadians will see improved accountability and they will witness firsthand how their money is changing and improving the system.

I would be remiss if I did not point out the important role that the Romanow commission, the Senate committee, the Kirby committee, and the many other studies that individual provinces commissioned in recent years played in the accomplishments found in the accord. The work of those commissions helped to clarify the direction government should take to meet Canadians expectations of an effective, efficient and accountable health care system.

I do however want to say a few words about the health council which in fact I know many hon. members are very interested in. My colleague, Nova Scotia's Minister of Health, the Hon. Jane Purves and I recently announced that an unexpected combination of issues, in particular the outbreak of SARS, have led to a short delay in finalizing the work surrounding the health council. Having said that, I want to reassure everyone in the House that we are making serious progress and I expect the announcement of the shape and work of the health council to take place within a few weeks.

Let me briefly turn to a second key priority for my department and that is first nations and Inuit health. Closing the obvious and troubling gap in health status between aboriginal and non-aboriginal Canadians is a continuing priority for our government.

As I noted earlier, when it comes to expenditures, my department is the fifth largest provider of direct health care services in this country. That results in our having the same need to get the best results from finite resources that our provincial and territorial partners have within their own health care systems.

The first ministers' health accord recognized this role. The Government of Canada followed through in budget 2003 with $1.3 billion new dollars in funding dedicated to first nations and Inuit health programs. This will help ease the fiscal pressures on health services and programs for first nations and Inuit, and provide much needed new money for nursing and capital development on reserves. The funding will also support the development of a first nations immunization strategy for on reserve children.

Beyond these and other initiatives my department is working with our partners in aboriginal communities, other federal departments, and the provinces and territories to improve the quality of primary care, prevention and health promotion services. We will continue to be engaged with our partners through community based initiatives such as healthy child development and chronic disease prevention efforts.

I have talked about two of our priorities. The third priority is safety and health protection. Achieving positive health results for all Canadians requires efforts to protect Canadians against risks to health presented by consumer product and disease.

Accordingly, the third Health Canada priority is safety and health protection. There has been a great deal of attention to this area in the past few weeks as we have taken on the challenges of SARS and West Nile virus. The work here goes much further. For example, it includes our legislative responsibility to regulate the safety and efficacy of therapeutic products. This is a function that brings together varied commitments and responsibilities. We are working to respond to the needs of Canadians for quick access to new drugs, treatments and medical devices while at the same time protecting Canadians against the marketing of unsafe and ineffective products.

We are increasing our focus on emergency preparedness in a time that continues to be volatile so that we are prepared to respond to potential threats related to bioterrorism or an outbreak of an emerging or re-emerging infectious disease. This scope of responsibility is reflected in the wide range of activities undertaken in the federal government's response to the recent outbreak of SARS.

I want to say a few words about the work that Health Canada is taking in relation to West Nile virus. Health Canada was a key and instrumental partner with the provinces and local public health authorities in the fight against SARS.

Again, let me commend those on the front lines, especially in the city of Toronto, as we controlled and contained that outbreak and became a model for the WHO in relation to how other countries could go about controlling containment. However, in the world in which we live we now have a new challenge posed by West Nile virus.

In close collaboration with the provinces we are moving forward with national surveillance, attention to the safety of Canada's blood supply, and diagnostic testing. We continue to invest in public education, partnerships with first nations communities at risk, and the assessment of commonly used pesticides and insect repellants.

Let me briefly touch upon our fourth key priority in our three year business plan which is balancing the health agenda. This commitment is based on a simple reality that factors ranging from our living and working conditions to our community support networks and to our individual health practices all combine to affect the state of our health. The more we can effectively influence these factors and take action on disease prevention, health protection and promotion, the more we can improve the long term health of Canadians and reduce the burden on our health care system.

Accordingly, the 2002 Speech from the Throne included a commitment to encourage healthy living, physical activity and illness prevention. We are engaged in transforming that commitment into action with a particular focus on building a collaborative healthy living strategy. The resulting strategy will provide the support Canadians need to improve their health and reduce health disparities.

The final priority set out in the report on plans and priorities is improving accountability to Canadians. It is one that I have implicitly incorporated throughout my comments this evening. Accountability is critical in demonstrating to Canadians how well we serve them using their tax dollars.

The federal health agenda is based on partnerships achieving results. While there are clear and well known areas of direct federal responsibility in health, we are taking action across our agenda with a clear commitment to working with others: with the provinces and territories; with health professionals and workers; with colleagues in other countries; with researchers; and with communities and individual Canadians.

We have an ambitious agenda, but given the importance of health issues to Canadians and to the quality of life for everyone in this country, an ambitious agenda is precisely what we should have. I am confident that the plans and priorities described in this year's main estimates document will go a long way toward meeting the needs of Canadians.